SIGNAL-AA | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

10,009 results for “SIGNAL-AA”

Trials

View all 7558 →

Active, not recruiting

A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

75 participants · First posted Aug 30, 2023

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

72 participants · First posted Oct 21, 2024

Treatment of AA Amyloidosis

1 participants · First posted May 2, 2024

Drugs

View all 374 →

AA-001

AA-102

AA-2311

Organizations

View all 304 →

Gene Signal SAS

France

BIO-SIGNAL GROUP CORP.

United States

Green Signal Biopharma Private Limited

News

View all 1773 →

Q32 Bio Restructures to Advance Bempikibart Development for Alopecia Areata Treatment

Q32 Bio Names Adrien Sipos as Interim CMO to Lead Alopecia Areata Drug Development

Q32 Bio Reports Positive Clinical Progress for Bempikibart in Alopecia Areata with 36-Week Data Expected Mid-2026

Page 1 of 1001